Mycartis N.v.

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Pronota N.v.

Pronata N.v.

Biocartis, Nv

Griet Vanpoucke

Koen Kas

Piet Moerman

Frans Van Roy

Barbara Janssens

Steven Goossens

Sven Degroeve

Kathleen Huijben

A method is described for treating a subject having acute heart failure (AHF) by measuring PERLECAN levels in the subject. The PERLECAN level in the subject is used to determine risk of mortality within one year for the subject. Treatment is selected on the basis of the outcome of the assay.

Method to determine treatment of acute heart failure

The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.

Perlecan as a biomarker for renal dysfunction

Methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression levels of the biomarkers Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) and TREM-like receptor transcript-1 (TLT1) as an indication of the condition of the patient, alone or in combination with further sepsis markers are disclosed. If the levels of the biomarkers indicate the presence of sepsis, the patient is treated for sepsis with an antibiotic and/or fluid resuscitation treatment.

Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof

Method of treating renal dysfunction based on perlecan as a biomarker

The present invention relates to a novel &#x3b1;-catenin with a new, specific expression pattern in mainly heart and testis. The invention further relates to the use of this &#x3b1;-catenin in the prediction, diagnosis, and/or treatment of cadherin-catenin related diseases, in particular cardiomyopathies and male infertility.

&#x3b1;-catenin expressed in heart and testis

Growing community of inventors

Merelbeke, Belgium

Griet Vanpoucke